Fenwick is a sponsor of the 2022 BIO IP Counsels Committee (IPCC) Conference. The conference offers timely, relevant educational sessions on the latest issues in the biotech IP sector.
Fenwick intellectual property partner Carl Morales will moderate and litigation partner Ryan Johnson will serve on a panel discussing key issues related to “carve outs” and the implications of the GlaxoSmithKline LLC v. Teva Pharms. USA, Inc. series of decisions for induced infringement of method patents. The session—taking placing on Tuesday, November 15—will cover:
- What does the GSK v. Teva series of decisions mean for the law of “carve outs” and induced infringement of method claims?
- Is the extensive commentary about and interest in this case warranted? What are the implications for both innovators and generics?
- What new approaches and strategies are we seeing, post-GSK v. Teva?
- What will the Supreme Court do with this dispute (if anything)?
View a detailed schedule of the conference and list of speakers here.